Koshkin, V. S., Henderson, N., Kilari, D., Jindal, T., Alhalabi, O., Freeman, D., … Alva, A. S. (2023). Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Koshkin, Vadim S., Nicholas Henderson, Deepak Kilari, Tanya Jindal, Omar Alhalabi, Dory Freeman, Arnab Basu, et al. “Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Koshkin VS, Henderson N, Kilari D, Jindal T, Alhalabi O, Freeman D, et al. Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Koshkin, Vadim S., et al. “Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023.

Koshkin VS, Henderson N, Kilari D, Jindal T, Alhalabi O, Freeman D, Basu A, Barata PC, Bilen MA, Zakharia Y, Emamekhoo H, Shah S, Milowsky MI, Davis NB, Gupta S, Hoimes CJ, Grivas P, Bellmunt J, Campbell MT, Alva AS. Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY. 2023.